Clinic-Oriented Feasibility of a Sensor-Fused Wearable for Upper-Limb Function

TL;DR

This study demonstrates a sensor-fused wearable device that provides low-latency assistance during upper-limb activities, reducing tremor and improving movement metrics in healthy adults, supporting future patient studies.

Contribution

It introduces a lightweight, multimodal wearable with real-time inference and safety features, showing feasibility for aiding upper-limb function during daily tasks.

Findings

Tremor Index decreased significantly

Range of motion increased by 12.65%

Task repetitions improved by nearly 3 per minute

Abstract

Background: Upper-limb weakness and tremor (4--12 Hz) limit activities of daily living (ADL) and reduce adherence to home rehabilitation. Objective: To assess technical feasibility and clinician-relevant signals of a sensor-fused wearable targeting the triceps brachii and extensor pollicis brevis. Methods: A lightweight node integrates surface EMG (1 kHz), IMU (100--200 Hz), and flex/force sensors with on-device INT8 inference (Tiny 1D-CNN/Transformer) and a safety-bounded assist policy (angle/torque/jerk limits; stall/time-out). Healthy adults (n = 12) performed three ADL-like tasks. Primary outcomes: Tremor Index (TI), range of motion (ROM), repetitions (Reps min$^{-1}$). Secondary: EMG median-frequency slope (fatigue trend), closed-loop latency, session completion, and device-related adverse events. Analyses used subject-level paired medians with BCa 95\% CIs; exact Wilcoxon $p$-values are reported in the Results. Results: Assistance was associated with lower tremor prominence and improved task throughput: TI decreased by $-0.092$ (95\% CI [$-0.102$, $-0.079$]), ROM increased by $+12.65\%$ (95\% CI [$+8.43$, $+13.89$]), and Reps rose by $+2.99$ min$^{-1}$ (95\% CI [$+2.61$, $+3.35$]). Median on-device latency was 8.7 ms at a 100 Hz loop rate; all sessions were completed with no device-related adverse events. Conclusions: Multimodal sensing with low-latency, safety-bounded assistance produced improved movement quality (TI $\downarrow$) and throughput (ROM, Reps $\uparrow$) in a pilot technical-feasibility setting, supporting progression to IRB-approved patient studies. Trial registration: Not applicable (pilot non-clinical).